Research Analysts Issue Forecasts for BIO FY2024 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research increased their FY2024 EPS estimates for shares of Bio-Rad Laboratories in a research note issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $10.18 for the year, up from their previous forecast of $9.46. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

Several other equities analysts have also recently issued reports on the company. Citigroup raised their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Royal Bank of Canada raised their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $391.80.

Bio-Rad Laboratories Trading Up 1.0 %

NYSE:BIO opened at $336.09 on Monday. Bio-Rad Laboratories has a 52 week low of $262.12 and a 52 week high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The company has a market cap of $9.41 billion, a PE ratio of -12.30 and a beta of 0.93. The business’s 50 day moving average is $340.63 and its two-hundred day moving average is $316.68.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.33 earnings per share.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several large investors have recently bought and sold shares of BIO. Van ECK Associates Corp lifted its stake in shares of Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after acquiring an additional 644,530 shares during the period. Select Equity Group L.P. lifted its position in Bio-Rad Laboratories by 26.2% in the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after purchasing an additional 134,856 shares during the period. First Eagle Investment Management LLC boosted its stake in Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares in the last quarter. Earnest Partners LLC boosted its stake in Bio-Rad Laboratories by 17.8% during the 2nd quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company’s stock valued at $165,720,000 after purchasing an additional 91,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after purchasing an additional 193,700 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Activity

In related news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This represents a 28.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. This represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.